Anjo J Veerman

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Twinning: a rewarding scenario for development of oncology services in transitional countries
    A J P Veerman
    Department of Pediatric Hematology Oncology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    Pediatr Blood Cancer 45:103-6. 2005
  2. pmc Long-term effects of cranial irradiation and intrathecal chemotherapy in treatment of childhood leukemia: a MEG study of power spectrum and correlated cognitive dysfunction
    Marita Daams
    Department of Clinical Child and Adolescent Studies, Faculty of Social Sciences and Leiden Institute for Brain and Cognition, Leiden University, Wassenaarseweg 52, P, O, Box 9555, 2300 RB, Leiden, The Netherlands
    BMC Neurol 12:84. 2012
  3. pmc Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia
    Mei N Sitaresmi
    Department of Pediatrics, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
    Health Qual Life Outcomes 6:96. 2008
  4. doi request reprint Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)
    Anjo J Veerman
    Dutch Childhood Oncology Group, The Hague, Netherlands
    Lancet Oncol 10:957-66. 2009
  5. ncbi request reprint In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups
    N L Ramakers-van Woerden
    Department of Pediatric Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Med Pediatr Oncol 38:379-86. 2002
  6. ncbi request reprint Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience
    A M Slats
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 19:537-44. 2005
  7. ncbi request reprint Reply to Gaipa et Al
    A J van der Sluijs-Gelling
    Leukemia 19:1858. 2005
  8. ncbi request reprint Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
    M van Grotel
    Department of Pediatric Oncology Hematology, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 22:124-31. 2008
  9. doi request reprint Circumvention of glucocorticoid resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Leuk Res 32:1417-23. 2008
  10. ncbi request reprint Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan, Amsterdam, The Netherlands
    Leukemia 18:530-7. 2004

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Twinning: a rewarding scenario for development of oncology services in transitional countries
    A J P Veerman
    Department of Pediatric Hematology Oncology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    Pediatr Blood Cancer 45:103-6. 2005
  2. pmc Long-term effects of cranial irradiation and intrathecal chemotherapy in treatment of childhood leukemia: a MEG study of power spectrum and correlated cognitive dysfunction
    Marita Daams
    Department of Clinical Child and Adolescent Studies, Faculty of Social Sciences and Leiden Institute for Brain and Cognition, Leiden University, Wassenaarseweg 52, P, O, Box 9555, 2300 RB, Leiden, The Netherlands
    BMC Neurol 12:84. 2012
    ..This study evaluates oscillatory neuronal activity in these long-term survivors. Power spectrum deviations are hypothesized to correlate with cognitive dysfunction...
  3. pmc Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia
    Mei N Sitaresmi
    Department of Pediatrics, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
    Health Qual Life Outcomes 6:96. 2008
    ..The aims of this study were to assess the HRQOL in childhood acute lymphoblastic leukemia (ALL) patients in Indonesia and to assess the influence of demographic and medical characteristics on HRQOL...
  4. doi request reprint Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)
    Anjo J Veerman
    Dutch Childhood Oncology Group, The Hague, Netherlands
    Lancet Oncol 10:957-66. 2009
    ..We aimed to confirm the results of the most effective DCOG ALL protocol for non-high-risk (NHR) patients to date (ALL-6), compare results with ALL-7 and ALL-8, and study prognostic factors in a non-randomised setting...
  5. ncbi request reprint In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups
    N L Ramakers-van Woerden
    Department of Pediatric Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Med Pediatr Oncol 38:379-86. 2002
    ..The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL)...
  6. ncbi request reprint Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience
    A M Slats
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 19:537-44. 2005
    ..We conclude that mortality dropped favorably in ALL, but not in AML. Especially for AML, effective but less toxic therapy and better supportive care guidelines need to be developed...
  7. ncbi request reprint Reply to Gaipa et Al
    A J van der Sluijs-Gelling
    Leukemia 19:1858. 2005
  8. ncbi request reprint Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
    M van Grotel
    Department of Pediatric Oncology Hematology, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 22:124-31. 2008
    ..Most cases with lower TAL1 levels were HOX11L2 or CALM-AF10 positive. NOTCH1 mutations did not predict for outcome. Classification into T-cell developmental subgroups was not predictive for outcome...
  9. doi request reprint Circumvention of glucocorticoid resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Leuk Res 32:1417-23. 2008
    ..Meta-iodobenzylguanidine however, partially reversed glucocorticoid resistance in 19% of the lymphoblastic leukemia samples...
  10. ncbi request reprint Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan, Amsterdam, The Netherlands
    Leukemia 18:530-7. 2004
    ..The association between GRgamma expression and in vitro GC resistance in iALL and the decreased protein/mRNA ratio in rALL, a subgroup resistant to GCs, warrants further exploration...
  11. ncbi request reprint In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype
    N L Ramakers-van Woerden
    VU University Medical Center, Department of Pediatric Hematology Oncology, Amsterdam, The Netherlands
    Leukemia 18:521-9. 2004
    ..The role of MLL cannot be excluded, with the t(4;11) being of special significance, while age appears to play a smaller role...
  12. ncbi request reprint Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia
    M L den Boer
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    J Clin Oncol 21:3262-8. 2003
    ....
  13. pmc Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia
    P Kaaijk
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 88:775-81. 2003
    ..In conclusion, cell proliferation differs between leukaemia subgroups and increased proliferation is associated with increased in vitro sensitivity to several anticancer agents in initial ALL...
  14. ncbi request reprint Clinical significance of cellular drug resistance in childhood leukemia
    G J L Kaspers
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    Recent Results Cancer Res 161:196-220. 2003
    ..The data are more and more being used and being considered for use in clinical trials in leukemia...
  15. ncbi request reprint Overview: chemotherapy for retinoblastoma: an expanding area of clinical research
    A Y N Schouten-van Meeteren
    Department of Pediatrics, Division of Hemato Oncology, Vrije Universiteit Medical Center, VUMC, Amsterdam
    Med Pediatr Oncol 38:428-38. 2002
  16. ncbi request reprint In vitro glucocorticoid resistance in childhood leukemia correlates with receptor affinity determined at 37 degrees C, but not with affinity determined at room temperature
    E G Haarman
    Leukemia 16:1882-4. 2002
  17. ncbi request reprint Features of proliferation and in vitro drug resistance in central primitive neuro-ectodermal tumours
    A Y N Schouten van Meeteren
    Department of Pediatrics, Subdivision Haemato oncology, Vrije Universiteit Medical Centre, Amsterdam
    Neuropathol Appl Neurobiol 28:200-9. 2002
    ..These findings suggest a cell cycle dependent activity of cytostatic drugs in vitro...
  18. ncbi request reprint Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance
    N L Ramakers-van Woerden
    Leukemia 16:949-51. 2002
  19. doi request reprint Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
    I M Appel
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands
    Leukemia 22:1665-79. 2008
    ..This may be explained by the rapid removal of apoptotic cells from the circulation in vivo. One additional dose of PEG-asparaginase upfront ALL treatment did not lead to other severe toxicities...
  20. ncbi request reprint BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996)
    W A Kamps
    Dutch Childhood Leukemia Study Group, The Hague, The Netherlands
    Leukemia 16:1099-111. 2002
    ..No benefit was observed from treatment intensification with HD-L-ASP in SRG patients, nor from HD-6MP in MRG patients...
  21. ncbi request reprint Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death
    A J van der Sluijs-Gelling
    Leukemia 19:1845-7. 2005
  22. ncbi request reprint A three-year-old girl with a yolk sac tumor in the orbit/maxillary sinus
    D Bresters
    Med Pediatr Oncol 40:70-1. 2003
  23. ncbi request reprint Do minor differences in primary therapy influence rescue-ability after relapse in childhood ALL?
    C M Zwaan
    Pediatr Blood Cancer 45:2-4. 2005
  24. ncbi request reprint Online fluorescent method to assess BCRP/ABCG2 activity in suspension cells
    J H Hooijberg
    Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 23:1451-4. 2004
    ..8226/MR cells displayed a larger cellular efflux rate of the BCRP substrate Hoechst 33342, as compared to the wildtype cells. This difference in efflux rate was completely decreased in the presence of the BCRP inhibitor Ko143...